RxDoctor Payments Data

Kausalya Pendyal, MD

Family Medicine · Richmond, VANPI 1831188119

Payments from drug & device makers

$6,896in general payments, 2019–2025

Across 418 payments — averaging $16.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$993
  • AbbVie$789
  • Pfizer$775
  • Lilly USA, LLC$767
  • AstraZeneca$729
  • Boehringer Ingelheim$237
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$6,890100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,896 in reported general payments places this provider in the 90th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$126,428
Medicare patients
641
Services billed
2,027

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide98$163,978
OzempicSemaglutide114$140,871
JardianceEmpagliflozin138$137,754
FarxigaDapagliflozin Propanediol128$135,918
EliquisApixaban104$109,179
MounjaroTirzepatide54$75,686
XareltoRivaroxaban47$41,218
EntrestoSacubitril/Valsartan14$19,118
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog29$17,267
Spiriva HandihalerTiotropium Bromide16$15,791
JanuviaSitagliptin Phosphate11$13,779
Tresiba Flextouch U-100Insulin Degludec22$11,570
Lantus SolostarInsulin Glargine,hum.Rec.Anlog90$10,063
SymbicortBudesonide/Formoterol Fumarate19$9,520
Atorvastatin Calcium1,121$8,323

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$767$239,665152 claims
AstraZenecaFarxiga, Symbicort$729$145,439147 claims
Novo NordiskOzempic$993$140,871114 claims
Boehringer IngelheimJardiance$237$137,754138 claims
PfizerEliquis$775$109,179104 claims
Johnson & JohnsonXarelto$14$41,21847 claims
NovartisEntresto$122$19,11814 claims
MerckJanuvia$70$13,77911 claims
AbbVieCreon, Synthroid$789$6,88365 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →